Spyre Therapeutics, Inc. (SYRE)
NASDAQ: SYRE · Real-Time Price · USD
70.01
+0.59 (0.85%)
May 4, 2026, 1:43 PM EDT - Market open
Spyre Therapeutics Employees
Spyre Therapeutics had 102 employees as of December 31, 2025. The number of employees increased by 37 or 56.92% compared to the previous year.
Employees
102
Change
37
Growth
56.92%
Revenue / Employee
n/a
Profits / Employee
-$1,240,608
Market Cap
6.04B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 102 | 37 | 56.92% |
| Sep 30, 2025 | 95 | 35 | 58.33% |
| Jun 30, 2025 | 87 | 27 | 45.00% |
| Mar 31, 2025 | 73 | 43 | 143.33% |
| Dec 31, 2024 | 65 | 35 | 116.67% |
| Sep 30, 2024 | 60 | 46 | 328.57% |
| Dec 31, 2023 | 30 | -39 | -56.52% |
| Jun 30, 2023 | 14 | -78 | -84.78% |
| Mar 31, 2023 | 61 | -38 | -38.38% |
| Dec 31, 2022 | 69 | -32 | -31.68% |
| Sep 30, 2022 | 69 | -21 | -23.33% |
| Jun 30, 2022 | 92 | 1 | 1.10% |
| Mar 31, 2022 | 99 | 11 | 12.50% |
| Dec 31, 2021 | 101 | 11 | 12.22% |
| Sep 30, 2021 | 90 | 3 | 3.45% |
| Jun 30, 2021 | 91 | 8 | 9.64% |
| Mar 31, 2021 | 88 | 9 | 11.39% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Rhythm Pharmaceuticals | 414 |
| Mirum Pharmaceuticals | 372 |
| Scholar Rock Holding | 289 |
| Apogee Therapeutics | 261 |
| Cogent Biosciences | 258 |
| Celcuity | 155 |
| CG Oncology | 142 |
| Protagonist Therapeutics | 132 |
SYRE News
- 2 days ago - Spyre Therapeutics Announces Grants of Inducement Awards - GlobeNewsWire
- 17 days ago - Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $463.5 Million - GlobeNewsWire
- 19 days ago - Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock - GlobeNewsWire
- 20 days ago - Spyre Therapeutics Announces Proposed Public Offering of its Common Stock - GlobeNewsWire
- 21 days ago - Spyre Therapeutics Breaks Higher On Positive Data From Ulcerative Colitis Drug - Benzinga
- 21 days ago - Spyre Therapeutics Transcript: Study result - Transcripts
- 21 days ago - Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients - GlobeNewsWire
- 23 days ago - Spyre Therapeutics to Host Conference Call to Report SPY001 Part A Induction Topline Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients on April 13, 2026 - GlobeNewsWire